News & Updates

Show Multimedia Only

Secukinumab yields sustained positive effects on molecular, histopathologic psoriasis markers

01 Apr 2023

Treatment with secukinumab leads to sustained clinical response among patients with psoriasis, with clinical response being associated with rapid and persistent normalization of keratin 16 (K16) and inflammatory gene expression for most patients, according to data from the ObePso-S study.

Secukinumab yields sustained positive effects on molecular, histopathologic psoriasis markers

01 Apr 2023

Systemic antihypertensive medications exert diverse effects on glaucoma, IOP

31 Mar 2023

The effects of systemic antihypertensive medications on glaucoma and intraocular pressure (IOP) appear to vary widely, according to the results of a systematic review and meta-analysis.

Systemic antihypertensive medications exert diverse effects on glaucoma, IOP

31 Mar 2023

Certain ART combinations carry some risk of depression among women with HIV

31 Mar 2023 by

Women with HIV who use antiretroviral therapy (ART) combinations such as tenofovir alafenamide (TAF) with a cobicistat-boosted integrase inhibitor (INSTI) or protease inhibitor (PI) appear to frequently show somatic depressive symptoms, according to data from the Women’s Interagency HIV Study (WIHS) presented at CROI 2023.

Certain ART combinations carry some risk of depression among women with HIV

31 Mar 2023

Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection

31 Mar 2023

A recent study has found a small-molecule covalently closed circular DNA (cccDNA) inhibitor that reduces levels of hepatitis B virus (HBV) cccDNA. This discovery offers a new way to cure patients with chronic HBV infection.

Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection

31 Mar 2023

Indapamide prevents death, cardiac events in at-risk patients

31 Mar 2023 by

Long-term treatment with indapamide with or without perindopril-based therapy results in a significant reduction in the risk of all-cause mortality, cardiovascular death, fatal stroke, and total stroke among patients with medium to high cardiovascular risk, according to a pooled analysis of four trials.

Indapamide prevents death, cardiac events in at-risk patients

31 Mar 2023

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

31 Mar 2023

Cyclophosphamide (CYC) and rituximab (RTX) show comparable therapeutic effects on ear, nose, and throat (ENT) symptoms in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

31 Mar 2023

Antibiotics linked to higher EAC risk

31 Mar 2023

Exposure to any antibiotics appears to contribute to an increase in the risk of esophageal adenocarcinoma (EAC), with the risk rising as the cumulative days of exposure increases, according to a study.

Antibiotics linked to higher EAC risk

31 Mar 2023

Original New Drug Application Approvals by US FDA (16-31 March 2023)

31 Mar 2023

New drug applications approved by US FDA as of 16-31 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2023)

31 Mar 2023

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

30 Mar 2023

Treatment with tenofovir disoproxil fumarate (TDF) yields similar rates of recurrence and overall survival as does entecavir in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), according to a study.

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

30 Mar 2023

Ceftolozane/tazobactam safe, effective in complicated UTI

30 Mar 2023 by

Combination therapy with ceftolozane and tazobactam demonstrates a favourable safety profile in children with complicated urinary tract infection (cUTI) similar to that of meropenem and to the previously reported safety profile in adults with cUTI, a study has shown.

Ceftolozane/tazobactam safe, effective in complicated UTI

30 Mar 2023

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Secukinumab yields sustained positive effects on molecular, histopathologic psoriasis markers

Secukinumab yields sustained positive effects on molecular, histopathologic psoriasis markers

Systemic antihypertensive medications exert diverse effects on glaucoma, IOP

Systemic antihypertensive medications exert diverse effects on glaucoma, IOP

Certain ART combinations carry some risk of depression among women with HIV

Certain ART combinations carry some risk of depression among women with HIV

Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection

Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection

Indapamide prevents death, cardiac events in at-risk patients

Indapamide prevents death, cardiac events in at-risk patients

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV

Antibiotics linked to higher EAC risk

Antibiotics linked to higher EAC risk

Original New Drug Application Approvals by US FDA (16-31 March 2023)

Original New Drug Application Approvals by US FDA (16-31 March 2023)

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

Ceftolozane/tazobactam safe, effective in complicated UTI

Ceftolozane/tazobactam safe, effective in complicated UTI